Patients with synovial sarcomas (N = 9) that expressed cytoplasmatic CXCR4 in surgical biopsies after neoadjuvant treatment showed unfavorable RFS [17.3 months (95% CI: 7.22–27.40) in positive CXCR4 versus not reached in negative CXCR4; p = 0.003] (Figure 4A). Here, CXCR4 is linked to synovial sarcoma.